Loading…
Lobbying Spend
—
Filings
6
Firms Hired
1
Active Period
2006–2007
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Medicare Prescription Drug Price Negotiation Act of 2007
2007 · year_end · Firm: ML STRATEGIES, LLC
* Medicare part D program (32 USC 1395w), drug coverage and reimbursement issues. H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007, all provisions included therein Medicare part D program (32 USC 1395w), drug coverage and reimbursement issues. H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007, all provisions included therein
Client expense: — · Firm income: $100,000
Matched citations: H.R. 4
Enhancing Drug Safety and Innovation Act of 2007
2007 · year_end · Firm: ML STRATEGIES, LLC
S 484, Enhancing Drug Safety and Innovation Act of 2007, Title 1, drug safety; and Title 3, clinical trials registry and results. Federal Food, Drug and Cosmetic Act (21 USC 301), Chapters 1-9 as they relate to the review, approval and regulation of drugs biologics and devices.
Client expense: — · Firm income: $100,000
Matched citations: S 484
Medicare Prescription Drug Price Negotiation Act of 2007
2007 · mid_year · Firm: ML STRATEGIES, LLC
* Medicare part D program (32 USC 1395w), drug coverage and reimbursement issues. H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007, all provisions included therein Medicare part D program (32 USC 1395w), drug coverage and reimbursement issues. H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007, all provisions included therein
Client expense: — · Firm income: $100,000
Matched citations: H.R. 4
Enhancing Drug Safety and Innovation Act of 2007
2007 · mid_year · Firm: ML STRATEGIES, LLC
S 484, Enhancing Drug Safety and Innovation Act of 2007, Title 1, drug safety; and Title 3, clinical trials registry and results. Federal Food, Drug and Cosmetic Act (21 USC 301), Chapters 1-9 as they relate to the review, approval and regulation of drugs biologics and devices.
Client expense: — · Firm income: $100,000
Matched citations: S 484
Medicare part D program (32 USC 1395w), drug coverage and reimbursement issues. HR4, Medicare Prescripton Drug Price Negotiation Act of 2007, all provisions included therein
Client expense: — · Firm income: $90,000
Matched citations: HR4
A bill to amend the Internal Revenue Code of 1986 to allow Federal civilian and military retirees to pay health insurance premiums on a pretax basis and to allow a deduction for TRICARE supplemental premiums.
2006 · year_end · Firm: ML STRATEGIES, LLC
S484, Enhancing Drug Safety and Innovation Act of 2007, Title 1, drug safety; and Title 3, clinical trials registry and results. Federal Food, Drug and Cosmetic Act (21 USC 301), Chapters 1-9 as they relate to the review, approval and regulation of drugs, biologics and devices.
Client expense: — · Firm income: $90,000
Matched citations: S484
Source: Senate LDA